No Data
No Data
Jinyao Pharmaceutical's Gastrointestinal Bleeding Drug Passes Consistency Evaluation
Tianjin Tianyao Pharmaceuticals (600488.SH): Famotidine Injection passed the consistency evaluation of generic drugs.
On July 24th, Gelunhui reported that Tianjin Tianyao Pharmaceuticals (600488.SH) announced that its subsidiary, Hubei Tianyao Pharmaceuticals Co., Ltd., received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration for Famotidine Injection and approved the consistency evaluation of generic drug quality and efficacy. Famotidine injection has been marketed both domestically and internationally, mainly used for upper gastrointestinal bleeding caused by peptic ulcer disease, and gastric and duodenal mucosal erosion and bleeding caused by various reasons other than tumors and esophageal and gastric fundus varices.
As of July 19, 2024, Tianjin Tianyao Pharmaceuticals (600488.SH) had 42,937 shareholders.
Tianjin Tianyao Pharmaceuticals (600488.SH) stated on the investor interaction platform on July 22 that as of July 19, 2024, the company had 42,937 shareholders.
Tianjin Tianyao Pharmaceuticals (600488.SH): Subsidiary adds new specifications for pharmaceutical products and passes generic drug consistency evaluation.
On July 22, Gelunhui reported that Tianjin Tianyao Pharmaceuticals (600488.SH) announced that its subsidiary, Tianjin Tianyao Heping Pharmaceutical Co., Ltd. (referred to as 'Tianyao Heping'), received the 'Drug Supplement Application Approval Notice' issued by the National Medical Products Administration for the injection of methylprednisolone succinate (20mg) (referred to as 'this drug' or 'this product'), approving this product for the consistency evaluation of generic drugs' quality and efficacy. Methylprednisolone succinate for injection is a glucocorticoid drug mainly used for anti-inflammatory treatment, immunosuppressive treatment, treatment of blood diseases and tumors, and treatment of shock.
Tianjin Tianyao Pharmaceuticals (600488.SH): Consistency evaluation passed for injection methylprednisolone succinate.
Tianjin Tianyao Pharmaceuticals (600488.SH) announced that its subsidiary, Tianjin Tianyao Heping Pharmaceutical Co., Ltd. (referred to as "...")
As of July 10, 2024, Tianjin Tianyao Pharmaceuticals (600488.SH) has 42,882 shareholders.
Tianjin Tianyao Pharmaceuticals (600488.SH) stated on the investor interaction platform on July 11 that as of July 10, 2024, the number of shareholders in the company was 42,882.
No Data